Should I Buy IDXX? IDXX 2026 Analysis

Should You Buy IDEXX Laboratories Inc (IDXX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

644.610

1 Day change

0.16%

52 Week Range

769.980

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy now: the stock is sitting just above key support (S1 ~635) with short-term oversold conditions and easing downside momentum, which favors an impatient “buy-it-now” rebound setup.
Sentiment backdrop is supportive: hedge funds are aggressively accumulating (+764% QoQ buying), options positioning/flow is call-skewed, and earnings/guidance were broadly solid even if the near-term outlook is mixed.
Base-case near-term path: rebound attempt toward the pivot (~667) first, then resistance around ~699 if momentum follows through.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock today.

Technical Analysis

Trend/Momentum: MACD histogram is negative (-7.139) but contracting, suggesting bearish momentum is fading rather than accelerating.
RSI: RSI(6) ~25.9 indicates short-term oversold conditions, often associated with reflex bounces (even if the broader trend isn’t fully reversed).
Moving averages: converging MAs point to a transition phase (compression) rather than a clean trend.
Key levels: Price 642.83 is below Pivot 666.98 (still technically under “trend pivot”), but holding above S1 635.10; upside targets are Pivot (~667) then R1 698.86; deeper support sits near S2 615.41.
Pattern-based expectation (given dataset): ~1.52% next week and ~9.25% next month bias suggests positive drift if support holds.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/flow: Put/Call OI ratio at 0.76 and very low Put/Call volume ratio at 0.1 indicate a bullish-to-risk-on tilt (calls dominating daily flow).
Activity: Today’s options volume (355) is ~160% of the 30-day average, signaling elevated attention/positioning.
Volatility: 30D IV ~28.92 vs HV ~26.34 (small premium); IV percentile ~55 is mid-range (not “cheap,” not extreme).

Technical Summary

Sell

Buy

Positive Catalysts

- Q4 2025 results were strong: EPS $3.08 (+17.6% YoY) and revenue +14.3% YoY, supporting the premium quality narrative.
- 2026 outlook implies continued growth: revenue guided to ~$4.632B–$4.720B (about 7.6%–9.6% growth).
- Product innovation and pet health demand cited as drivers in news flow.
- Fund flows: hedge funds are buying aggressively (+764% QoQ), a notable institutional tailwind.
- Options tape is call-skewed (sentiment supportive).

Neutral/Negative Catalysts

- Near-term growth concerns: commentary highlights potentially muted Q1 growth and pet visit headwinds (notably referenced as a drag into 2026).
- Margin outlook caution: UBS flagged a softer 2026 gross margin outlook and fewer near-term margin expansion drivers.
- Analyst target trims: at least two firms reduced price targets post-print, suggesting the market wanted a stronger forward setup.
- No supportive signal from Intellectia AI Stock Picker or SwingMax today (so this is not a “highest-conviction” systematic entry per the provided signals).

Financial Performance

Latest quarter (2025/Q4): Revenue $1.091B (+14.28% YoY), Net Income $248.2M (+14.82% YoY), EPS $3.08 (+17.56% YoY).
Profitability: Gross margin 60.35% (+0.92% YoY), showing resilience and slight expansion.
Overall read: high-quality growth quarter, but the forward narrative is more mixed (growth/margins/pet visits debated).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: price targets have been trimmed (UBS $750→$730; BTIG $830→$800) while ratings remain mixed (UBS Neutral; BTIG Buy).
Broader tone: still constructive longer-term (Barclays initiated Overweight with $850; BTIG remains Buy), but with near-term caution (UBS Neutral citing macro/margin/growth visibility; Piper remains Neutral despite raising PT earlier).
Wall Street pros: durable pet health demand, innovation, pricing power, strong Q4 execution.
Wall Street cons: potential slower near-term growth (pet visits/Q1), margin expansion less clear, and placement/uptake pacing concerns.
Politicians/congress/influentials: No recent congress trading data available; no notable insider trend (insiders neutral).

10 Analyst Rating

Wall Street analysts forecast IDXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDXX is 792.78 USD with a low forecast of 750 USD and a high forecast of 850 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

3 Hold

0 Sell

Moderate Buy

Current: 643.590

Low

750

Averages

792.78

High

850

Current: 643.590

Low

750

Averages

792.78

High

850

Barclays

Glen Santangelo

Overweight

downgrade

$850 -> $800

AI Analysis

2026-02-05

New

Reason

Barclays

Glen Santangelo

Price Target

$850 -> $800

AI Analysis

2026-02-05

New

downgrade

Overweight

Reason

Barclays analyst Glen Santangelo lowered the firm's price target on Idexx Laboratories to $800 from $850 and keeps an Overweight rating on the shares. The firm updated the company's model post the Q4 repot, saying the fiscal 2026outlook "underwhelmed."

UBS

Andrea Alfonso

Neutral

downgrade

$750 -> $730

2026-02-03

New

Reason

UBS

Andrea Alfonso

Price Target

$750 -> $730

2026-02-03

New

downgrade

Neutral

Reason

UBS analyst Andrea Alfonso lowered the firm's price target on Idexx Laboratories to $730 from $750 and keeps a Neutral rating on the shares. The print showed mixed signals, with early benefits from increased diagnostic use among aging "pandemic puppies" and pricing strength helping maintain a premium, but Q4 also raised concerns around muted Q1 growth, a softer 2026 gross margin outlook, and slower inVue placements in Year 2, the analyst tells investors in a research note. With macro headwinds and fewer near-term margin expansion drivers, the risk/reward appears balanced pending clearer evidence that recent pricing premiums are sustainable, the firm says.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IDXX

Unlock Now

IDXX Should I Buy

IDXX Should I Buy

Should You Buy IDEXX Laboratories Inc (IDXX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch